Get the Stockscreener App
20.16
7.12%
1.34
Pre-market:
20.17
0.01
+0.05%
Urogen Pharma Ltd stock is traded at $20.16, with a volume of 1.48M.
It is up +7.12% in the last 24 hours and down -2.66% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$18.82
Open:
$18.91
24h Volume:
1.48M
Relative Volume:
1.90
Market Cap:
$943.67M
Revenue:
$96.52M
Net Income/Loss:
$-164.64M
P/E Ratio:
-5.8231
EPS:
-3.4621
Net Cash Flow:
$-144.11M
1W Performance:
-2.47%
1M Performance:
-2.66%
6M Performance:
+7.23%
1Y Performance:
+110.00%
1-Day Range:
$18.11
$20.71
1-Week Range:
$18.04
$21.75
52-Week Range:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
20.16 | 880.94M | 96.52M | -164.64M | -144.11M | -3.4621 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile - simplywall.st
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation - Investing.com Australia
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating - TipRanks
NMIBC Market: Strong Pharma Growth Forecast Through 2034 - openPR.com
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales - Investing.com Australia
UroGen Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript - Insider Monkey
UroGen refinances debt with $250M facility at 8.25% rate - Investing.com India
UroGen Pharma Strengthens Balance Sheet, Reports FY25 Results And ZUSDURI Launch Progress - Nasdaq
Urogen Pharma Q4 2025 Earnings Call Transcript - MarketBeat
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives - simplywall.st
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026 - Meyka
UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Stron - GuruFocus
Akin, an Elite Global Law Firm - Akin
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales By Investing.com - Investing.com Australia
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5%Should You Sell? - MarketBeat
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts - Investing.com Nigeria
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales - Investing.com India
Urogen Pharma Q4 Earnings Call Highlights - MarketBeat
URGN: Analyst Maintains Buy Rating with $33 Target | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen (URGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
UroGen Pharma Amends Loan Agreement With Pharmakon Advisors - marketscreener.com
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
UroGen Pharma Q4 Net Loss Narrows, Revenue Rises - marketscreener.com
UroGen reports $15.8M in ZUSDURI sales, refinances debt - Investing.com India
UroGen Pharma (URGN) Secures Amended $250M Loan Agreement - GuruFocus
UroGen Pharma Secures New $250 Million Term Loan - TipRanks
UroGen's (URGN) Revenue Misses Estimates, Eyes Growth with ZUSDU - GuruFocus
UroGen Pharma (URGN) Projects Modest Growth in 2026 Jelmyto Sales - GuruFocus
UROGEN PHARMA ($URGN) Releases Q4 2025 Earnings - Quiver Quantitative
Urogen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
UroGen Pharma Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
UroGen Pharma (URGN) outlines RTGel cancer platform, Jelmyto, Zusduri and pipeline - Stock Titan
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - The Manila Times
UroGen Pharma (NASDAQ: URGN) inks $250M secured term loan deal - Stock Titan
UroGen Pharma Ltd. Enhances Financial Position with Amended Loan Agreement for Up to $250 Million - Quiver Quantitative
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Biotech UroGen lands $200M fixed-rate loan, payments pushed to 2030 - Stock Titan
UroGen Pharma: Q4 Earnings Insights - Sahm
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Monday - MarketBeat
Urogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
A Look At UroGen Pharma (URGN) Valuation After New Phase 3 ENVISION ZUSDURI Data - Yahoo Finance
Trading Systems Reacting to (URGN) Volatility - Stock Traders Daily
UroGen Pharma (URGN) director converts 2,000 RSUs into 2,000 ordinary shares - Stock Titan
UroGen Pharma Earnings Preview - Benzinga
UroGen Pharma Announces EORTC Recurrence Score Analysis of ZUSDURI™ to be Presented at ASCO-GU 2026 - Quiver Quantitative
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):